{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:23:17Z","timestamp":1780392197065,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00277-017-3012-z","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T21:38:14Z","timestamp":1495489094000},"page":"1303-1313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios"],"prefix":"10.1007","volume":"96","author":[{"given":"Giuseppe","family":"Saglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rowlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyna","family":"Gooden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milayna","family":"Subar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"3012_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","volume":"99","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Efficace F, Rosti G (2014) Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 99:205\u2013208","journal-title":"Haematologica"},{"key":"3012_CR2","unstructured":"Gleevec (imatinib) [package insert] (2015) Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"3012_CR3","unstructured":"Iclusig (ponatinib) [package insert] (2014) ARIAD Pharmaceuticals, Inc., Cambridge, MA"},{"key":"3012_CR4","unstructured":"Sprycel (dasatinib) [package insert] (2015) Bristol-Myers Squibb Company, Princeton, NJ"},{"key":"3012_CR5","unstructured":"Tasigna (nilotinib) [package insert] (2015) Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"3012_CR6","unstructured":"FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales [news release]; November 5 (2013) United States Food and Drug Administration website. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm373040.htm . Accessed 3 Mar 2016"},{"key":"3012_CR7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P (2015) Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 125:901\u2013906","journal-title":"Blood"},{"key":"3012_CR8","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","volume":"90","author":"J Cortes","year":"2015","unstructured":"Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT (2015) Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol 90:E66\u2013E72","journal-title":"Am J Hematol"},{"key":"3012_CR9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054","journal-title":"Leukemia"},{"key":"3012_CR10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C (2016) Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma 57:1300\u20131310","journal-title":"Leuk Lymphoma"},{"key":"3012_CR11","doi-asserted-by":"publisher","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM (2016) Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. doi: 10.1001\/jamaoncol.2015.5932","DOI":"10.1001\/jamaoncol.2015.5932"},{"key":"3012_CR12","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u0457ve Chronic Myeloid Leukemia Patients trial. J Clin Oncol 34:2333\u20132340","journal-title":"J Clin Oncol"},{"key":"3012_CR13","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"3012_CR14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","volume":"14","author":"JC Araujo","year":"2013","unstructured":"Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14:1307\u20131316","journal-title":"Lancet Oncol"},{"key":"3012_CR15","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207\u20133213","journal-title":"Blood"},{"issue":"suppl 1","key":"3012_CR16","first-page":"47","volume":"93","author":"J Cortes","year":"2008","unstructured":"Cortes J, Sawyers CL, Kantarjian H, Shah NP, Paquette R, Bleickardt E, Paliwal P, Talpaz M (2008) Dasatinib is associated with durable treatment responses in chronic phase chronic myeloid leukemia: long-term follow-up from the phase I trial. Haematologica 93(suppl 1):47 (abstract 0119)","journal-title":"Haematologica"},{"key":"3012_CR17","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143\u20134150","journal-title":"Blood"},{"key":"3012_CR18","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303\u20132309","journal-title":"Blood"},{"key":"3012_CR19","first-page":"889","volume":"33","author":"XJ Huang","year":"2012","unstructured":"Huang XJ, Hu JD, Li JY, Jin J, Meng FY, Shen ZX, Liu T, Wu DP, Wang JM, Wang JX (2012) Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 33:889\u2013895","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"3012_CR20","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, M\u00fcller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS (2009) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322\u20136329","journal-title":"Blood"},{"key":"3012_CR21","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143\u20135150","journal-title":"Blood"},{"key":"3012_CR22","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"3012_CR23","doi-asserted-by":"crossref","unstructured":"Trudel GC, Paliwal P, Lainas I (2012) Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): design of CA180-363, a phase II open-label randomized trial. J Clin Oncol 30(suppl) (abstract TPS6634)","DOI":"10.1200\/jco.2012.30.15_suppl.tps6634"},{"key":"3012_CR24","volume-title":"Introductory guide to MedDRA version 15.0","author":"MedDRA Maintenance and Support Services Organization","year":"2012","unstructured":"MedDRA Maintenance and Support Services Organization (2012) Introductory guide to MedDRA version 15.0. International Federation of Pharmaceutical Manufacturers and Associations, Chantilly"},{"key":"3012_CR25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/leu.2015.352","volume":"30","author":"PD Coutre le","year":"2016","unstructured":"le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE (2016) Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 30:1593\u20131596","journal-title":"Leukemia"},{"key":"3012_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40259-013-0056-z","volume":"28","author":"E Abruzzese","year":"2014","unstructured":"Abruzzese E, Breccia M, Latagliata R (2014) Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs 28:17\u201326","journal-title":"BioDrugs"},{"key":"3012_CR27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"3012_CR28","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V122.21.2726.2726","volume":"122","author":"D Rea","year":"2013","unstructured":"Rea D, Mirault T, Raffoux E, Miclea J-M, Rousselot P, Dombret H, Messas E (2013) Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib, using risk stratification for cardiovascular diseases (CVD). Blood 122:2726 (abstract)","journal-title":"Blood"},{"key":"3012_CR29","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, M\u00fcller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","DOI":"10.1056\/NEJMoa1306494"},{"key":"3012_CR30","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood.V124.21.3135.3135","volume":"124","author":"JE Cortes","year":"2014","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambarcorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian H (2014) Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 124:3135 (abstract)","journal-title":"Blood"},{"key":"3012_CR31","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despr\u00e9s JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2015) Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association. Circulation 131:e29\u2013e322","journal-title":"Circulation"},{"issue":"suppl 1","key":"3012_CR32","first-page":"437","volume":"100","author":"R Paquette","year":"2015","unstructured":"Paquette R, Mauro M, Simonsson B, Abruzzese E, Andorksy D, Hansen R, Subar M, Turner M, Zyczynski T, Mohamed H, Goldberg SL (2015) Cardiovascular (CV)-related hospitialization in patients with chronic-phase chronic myeloid leukemia (CP-CML) in SIMPLICITY, a prospective observational study. Haematologica 100(suppl 1):437 (abstract E1099)","journal-title":"Haematologica"},{"key":"3012_CR33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","volume":"86","author":"V Conteduca","year":"2013","unstructured":"Conteduca V, Di Lorenzo G, Tartarone A, Aieta M (2013) The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 86:42\u201351","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3012-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T06:43:04Z","timestamp":1602139384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3012-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}